Scancell has received the approvals required from UK regulatory authorities to initiate the Phase II study in metastatic melanoma with the ImmunoBody SCIB1 in patients receiving pembrolizumab (Merck’s Keytruda).
25 Apr 2019
Phase II melanoma study with SCIB1 to start in Q219
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Phase II melanoma study with SCIB1 to start in Q219
Scancell Holdings Plc (SCLP:LON) | 10.2 0 0.0% | Mkt Cap: 95.1m
- Published:
25 Apr 2019 -
Author:
Mick Cooper PhD -
Pages:
2
Scancell has received the approvals required from UK regulatory authorities to initiate the Phase II study in metastatic melanoma with the ImmunoBody SCIB1 in patients receiving pembrolizumab (Merck’s Keytruda).